Revenue recognition and accounts receivable (Tables)

3 Months Ended

Mar. 31, 2025

Revenue Recognition And Accounts Receivable [Abstract]

Schedule of Net Sales by Product Category by Reporting Segment

The table below presents net sales by product category by reporting segment:

	Three Months Ended March 31,
(Unaudited, U.S. Dollars, in thousands)	2025		2024		Change
Bone Growth Therapies	$	55,050	$	52,477		4.9	%
Spinal Implants, Biologics, and Enabling Technologies		108,786		108,816		0.0	%
Global Spine		163,836		161,293		1.6	%
Global Orthopedics		29,810		27,315		9.1	%
Net sales	$	193,646	$	188,608		2.7	%

Schedule of Components Net Sales

The table below presents product sales and marketing service fees, which are both components of net sales:

	Three Months Ended March 31,
(Unaudited, U.S. Dollars, in thousands)	2025		2024
Product sales	$	181,633	$	175,831
Marketing service fees		12,013		12,777
Net sales	$	193,646	$	188,608

Allowances for Expected Credit Losses

The following table provides a detail of changes in the Company’s allowance for expected credit losses for the three months ended March 31, 2025 and 2024:

	Three Months Ended March 31,
(Unaudited, U.S. Dollars, in thousands)	2025			2024
Allowance for expected credit losses beginning balance	$	7,418		$	7,130
Current period provision for expected credit losses		1,058			1,376
Write-offs charged against the allowance and other		(11	)		(19	)
Effect of changes in foreign exchange rates		137			(89	)
Allowance for expected credit losses ending balance	$	8,602		$	8,398